JANX实时信号 | 通过Getagraph.com最大化利润

出售 13274 min ago

@ $43.76

发出时间: 24 May 2024 @ 22:30

回报率: 22.27%

上一信号: May 24 - 00:50

上一信号: 购买

回报率: -2.20 %

Live Chart Being Loaded With Signals

Commentary (1 Jun 2024 @ 04:00):

Stats
今日成交量	779 919
平均成交量	771 358
市值	2.77B
EPS	$0 ( 2024-05-14 )
下一个收益日期	( $0 ) 2024-08-06
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-44.58
ATR14	$0.0950 (0.18%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-04	Ra Capital Management, L.p.	Buy	1 397 849	Pre-Funded Warrants (Right to Buy)
2024-02-29	Avalon Ventures Xi, L.p.	Sell	447 949	Common Stock
2024-02-29	Avalon Ventures Xi, L.p.	Sell	438 722	Common Stock
2024-02-29	Avalon Ventures Xi, L.p.	Sell	84 985	Common Stock
2024-02-29	Avalon Ventures Xi, L.p.	Buy	31 456	Common Stock

INSIDER POWER
55.49
Last 96 transactions
Buy: 16 444 752 \| Sell: 7 280 818

音量相关性

長: -0.19 (neutral)

短: -0.57 (weak negative)

Signal:(35.063) Neutral

Janux Therapeutics, Inc. 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Janux Therapeutics, Inc. 相关性 - 货币/商品

0.31
( neutral )

0.28
( neutral )

0.00
( neutral )

0.15
( neutral )

-0.11
( neutral )

0.30
( neutral )

Janux Therapeutics, Inc. 财务报表

Annual	2023
营收:	$8.08M
毛利润:	$6.13M (75.81 %)
EPS:	$-1.320

FY	2023
营收:	$8.08M
毛利润:	$6.13M (75.81 %)
EPS:	$-1.320

FY	2022
营收:	$8.61M
毛利润:	$7.77M (90.23 %)
EPS:	$-1.310

FY	2021
营收:	$3.64M
毛利润:	$0.00 (0.00 %)
EPS:	$-0.794

Financial Reports:

No articles found.

Janux Therapeutics, Inc. Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Janux Therapeutics, Inc.

Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company\'s lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. In addition, its EGFR-TRACTr is designed to target EGFR in many cancer types with multiple approved monoclonal antibodies. The company was incorporated in 2017 and is headquartered in La Jolla, California.